ATRA241220P1000
- 0.00
- 0.000.00%
Atara Biotherapeutics Newsroom
Kyverna Therapeutics Picks Former Atara Bio, Kite Executives for Leadership Roles
Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive...
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
Insider Sale: EVP of $ATRA (ATRA) Sells 1,000 Shares
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Raises Target Price to $21
Atara Biotherapeutics Price Target Raised to $21 From $13 at Canaccord
Atara Biotherapeutics Advances With Strategic Partnerships
Atara Biotherapeutics | 8-K: Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
Atara Biotherapeutics: Cash Runway Into 2027 Enables Key Pipeline Readouts >ATRA
Atara Biotherapeutics: First Patient Dosed for ATA3219 Non-Hodgkin's Lymphoma Study; Initial Clinical Data Expected 1Q of 2025 >ATRA
Atara Biotherapeutics: Tab-cel U.S. BLA On-Track With PDUFA Target Action Date of Jan 15, 2025 >ATRA
Atara Biotherapeutics | 10-Q: Q3 2024 Earnings Report
Atara Biotherapeutics Reports Q3 EPS ($2.93), Consensus ($1.93)
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q3 Revenue $40.2M
Express News | Atara Biotherapeutics Q3 Revenue USD 40.19 Million Vs. IBES Estimate USD 35.2 Million
Express News | Atara Biotherapeutics Q3 Net Income USD -21.909 Million
Here Are the Major Earnings After the Close Today
Insights Into Atara Biotherapeutics's Upcoming Earnings
Earnings Preview: ATRA to Report Financial Results Post-market on November 12